EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
    2.1.1.355 | Adenocarcinoma |
30903272 |
Robust expression of EZH2 in endocervical neoplastic lesions. |
diagnostic usage |
1 |
| 2.1.1.355 | Adenocarcinoma |
31398867 |
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer. |
diagnostic usage |
3 |
| 2.1.1.355 | Adenocarcinoma |
33639051 |
Effects of miR-362 in Regulating the Proliferation, Invasion and Apoptosis of Gastric Cancer by Inhibiting the Expression of Tumor-Promoting Factor PRDM2. |
diagnostic usage |
1 |
| 2.1.1.355 | Adenocarcinoma |
34094655 |
SETDB1 in cancer: overexpression and its therapeutic implications. |
diagnostic usage |
3 |
| 2.1.1.355 | Adenocarcinoma |
34413625 |
Histone Methyltransferases Useful in Gastric Cancer Research. |
diagnostic usage |
4 |
| 2.1.1.355 | Adenocarcinoma |
32360551 |
SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice. |
therapeutic application |
2 |
| 2.1.1.355 | Adenocarcinoma |
32729861 |
Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy. |
therapeutic application |
4 |
| 2.1.1.355 | Adenocarcinoma |
23395645 |
Enhancer of Zeste Homolog 2 Silences MicroRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin. |
therapeutic application |
1 |
| 2.1.1.355 | Adenocarcinoma |
31398867 |
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer. |
therapeutic application |
1 |
| 2.1.1.355 | Adenocarcinoma |
34094655 |
SETDB1 in cancer: overexpression and its therapeutic implications. |
therapeutic application |
3 |
